Medicare AdvantageCoverageMedium impact
MA08.184a, Cosibelimab-ipdl (Unloxcyt™)
Independence Blue Cross·Oncology·Pharmacy
Effective date
Jun 1, 2026
We identified it
Jun 19, 2026
Summary
New medical necessity criteria have been established for Cosibelimab-ipdl (Unloxcyt™), a specialty pharmacy medication. This policy defines when the medication will be covered and what documentation will be required for Medicare Advantage plans.
Action Required
Before June 1, 2026: Providers prescribing Cosibelimab-ipdl (Unloxcyt™) must review the new medical necessity criteria and ensure proper documentation is in place. Billing team should verify prior authorization requirements and update encounter forms to prompt providers for required documentation. Claims may be denied without meeting the new medical necessity criteria.